Available Brands
Did you find this information helpful?
Author Details

Written By
Sakshi Anil More
B. Pharm

Reviewed By
Dr. Tejashwin Adiga
MBBS
Last updated : 09 Oct 2026 | 06:49 AM (IST)

Want to know more?
Read Our Editorial Policy
Quick Summary
EFAVIRENZ,EMTRICITABINE,TENOFOVIR DISOPROXIL FUMARATE
Last updated on 09 Oct 2026 | 06:49 AM (IST)
EFAVIRENZ,EMTRICITABINE,TENOFOVIR DISOPROXIL FUMARATE
Molecule Overview
This is a fixed-dose combination of three antiretroviral medicines efavirenz, emtricitabine, and tenofovir disoproxil fumarate used together as a complete, once-daily regimen to treat HIV-1 infection. It belongs to a class of medicines called antiretroviral therapy (ART), combining drugs from two different mechanism classes. It is a prescription-only medicine.
Medical Classification
Therapeutic Class: Antiretroviral combination therapy for HIV-1.
Pharmacological Class: Non-nucleoside reverse transcriptase inhibitor (efavirenz) plus two nucleos(t)ide reverse transcriptase inhibitors (emtricitabine, tenofovir disoproxil fumarate).
Drug Family: Combination antiretroviral therapy (cART).
ATC Classification: J05AR06 (Efavirenz, emtricitabine and tenofovir disoproxil).
Conditions Treated
Approved: HIV-1 infection in adults and pediatric patients weighing at least 40 kg, as a complete regimen or in combination with other antiretroviral agents.
Commonly used for: People newly diagnosed with HIV or switching regimens, where a simplified single-tablet, once-daily combination is appropriate.
Off-label use (only under medical guidance): Not typically used off-label; dosing and use are governed by HIV treatment guidelines.
Available Strengths & Dosage Forms
● Oral tablets (fixed-dose combination): efavirenz 600 mg / emtricitabine 200 mg / tenofovir disoproxil fumarate 300 mg.
How the Molecule Works
Efavirenz blocks reverse transcriptase, an HIV enzyme, by binding to a different site than the other two drugs (a non-nucleoside mechanism), while emtricitabine and tenofovir disoproxil fumarate block the same enzyme by acting as faulty building blocks (nucleos(t)ide analogs) that stop the virus's genetic material from being copied. Together, these three drugs attack HIV replication at complementary points, helping keep the virus suppressed.
Dosage & Administration
Standard dose: One tablet taken orally once daily on an empty stomach, preferably at bedtime to reduce central nervous system side effects.
Condition-wise dose: Not recommended for patients with a creatinine clearance below 50 mL/min, as individual dose adjustment of the components is not possible in this fixed combination.
Route: Oral, once daily.
Missed dose: Take the missed dose as soon as remembered; if close to the next dose, skip it and continue as scheduled — don't double up.
Overdose: May cause increased central nervous system side effects or kidney-related changes; requires medical attention.
Side Effects
Common: Dizziness, vivid dreams, headache, rash, diarrhoea, nausea, and fatigue.
Serious: Severe skin reactions, liver toxicity, psychiatric symptoms (depression, suicidal thoughts, unusual behaviour) linked to efavirenz, kidney function decline, and reduced bone mineral density linked to tenofovir disoproxil fumarate.
Emergency symptoms: Severe rash with blistering, yellowing of the skin/eyes, signs of severe depression or suicidal thoughts, or a marked drop in urine output.
Recovery advice: Dizziness and vivid dreams from efavirenz are usually most pronounced in the first few weeks and often improve; taking the dose at bedtime on an empty stomach can reduce these effects.
Warnings & Precautions
Pregnancy: Used with caution; efavirenz has historically carried specific pregnancy precautions, so current guidance should be checked with the treating doctor.
Breastfeeding: Not generally recommended, in line with broader HIV-in-pregnancy/breastfeeding guidance to prevent transmission.
Liver disease: Used with caution; liver function is monitored, particularly given the hepatitis B interaction risk.
Kidney disease: Not recommended in patients with reduced kidney function, as described above.
Elderly: Limited specific data; used with routine monitoring.
Children: Approved for children weighing at least 40 kg; not recommended below this weight due to the fixed-dose combination.
Drug Interactions
● Other efavirenz-, emtricitabine-, or tenofovir-containing products: should not be combined with this medicine to avoid duplicate dosing.
● Strong CYP3A4 inducers/inhibitors: efavirenz both induces and is affected by this enzyme system, leading to numerous significant interactions with drugs like rifampin, certain antifungals, and hormonal contraceptives.
● Other nephrotoxic drugs (e.g., NSAIDs, certain antibiotics): may increase the risk of kidney effects when combined with tenofovir disoproxil fumarate.
● St. John's Wort and other herbal products: can significantly reduce efavirenz levels and is not recommended.
Monitoring Requirements
● Hepatitis B virus testing before starting and monitoring if the medicine is stopped.
● Kidney function tests (serum creatinine, estimated creatinine clearance) periodically.
● HIV viral load and CD4 count to monitor treatment response.
● Bone density assessment in patients with a history of fracture or risk factors for bone loss.
Alternative Molecules
Tenofovir alafenamide-based combinations, Dolutegravir-based regimens (integrase inhibitor-based, generally preferred in current treatment guidelines due to fewer CNS and bone/kidney effects).
Combination Therapies
This is itself a fixed triple combination intended as a complete regimen; not combined with other products containing the same three drugs. May be used alongside other antiretrovirals in specific treatment-experienced situations, under specialist guidance.
● HIV / Antiretroviral Medicines
● Fixed-Dose Combination ART
● Reverse Transcriptase Inhibitors
FAQs
Q1.
It's used as a complete, once-daily treatment regimen for HIV-1 infection in adults and children weighing at least 40 kg.
Q2.
Taking it at bedtime on an empty stomach can reduce dizziness, vivid dreams, and other nervous-system side effects linked to efavirenz.
Q3.
Because stopping this medicine in someone coinfected with hepatitis B can cause a serious flare-up of hepatitis B, so testing and monitoring are essential.
Q4.
Yes, the tenofovir disoproxil fumarate component can affect kidney function and bone density over time, so regular monitoring is recommended.
Q5.
No, it doesn't cure HIV, but taken consistently, it helps suppress the virus to very low levels, supporting long-term health and reducing transmission risk.
References
Disclaimer
The information on this page is for educational purposes only and is not a substitute for medical advice. Please consult your doctor to know if this treatment is appropriate for your condition.






